Tau Therapeutics And Xdynia Merge To Form Cavion
Monday, September 8, 2014
Managers and shareholders of both Tau Therapeutics LLC and Xdynia LLC approved a merger of the two companies and the surviving entity, Tau Therapeutics LLC, has been renamed Cavion LLC. The name “Cavion” reflects the combined company’s therapeutic approach of selectively inhibiting the Cav3 ion channel (T-type calcium channel).
Both Tau Therapeutics and Xdynia have been developing T-type calcium channel inhibitors for separate indications. Tau Therapeutics has worked to develop T-type calcium channel antagonists that improve the efficacy of standard chemotherapies and radiation therapies against solid tumor cancers. Xdynia has focused on inhibiting the T-type calcium channel to provide better treatments for the prevention and treatment of neuropathic pain and other neurologic diseases.
“The oncology and neurology fields predominate in diseases of high unmet medical need,” stated Cavion president and CEO Andrew Krouse, MALS. “The combination of Tau Therapeutics and Xdynia into one platform company will increase our ability to create innovative therapies for patients suffering with life-altering illnesses. We also believe that the merger adds tremendous value and even greater up-side potential than if either company moved forward alone.”
Cavion is currently conducting a multi-site NCI Adult Brain Tumor Consortium sponsored Phase 1b clinical trial of its proof of concept drug, mibefradil, administered with temozolomide to patients with recurrent glioblastoma. Cavion and the Yale Cancer Center have also launched a Phase 1b trial in recurrent brain cancer testing the use of mibefradil to enhance the effect of radiation on tumors by blocking the non-homologous end joining that DNA strands use to repair themselves after radiation. The company hopes to study the efficacy of a T-type calcium channel inhibitor against neuropathic pain in a Phase 2 clinical trial to commence in 2015. In addition to having mibefradil as a successful proof of concept, Cavion has accelerated its drug development program to create follow-on compounds with improved efficacy, safety and target selectivity.
Xdynia’s president and now Cavion’s Vice President of Neurology and Senior Medical Director, Yuri Maricich, MD, MBA, said, “I am excited to continue Xdynia’s mission to improve the lives of patients with neuropathic pain as part of Cavion.”